These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10748176)

  • 41. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
    Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
    Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.
    Blankenship C; Naglich JG; Whaley JM; Seizinger B; Kley N
    Oncogene; 1999 Feb; 18(8):1529-35. PubMed ID: 10102622
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein.
    Takagi Y; Pause A; Conaway RC; Conaway JW
    J Biol Chem; 1997 Oct; 272(43):27444-9. PubMed ID: 9341197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drosophila von Hippel-Lindau tumor suppressor complex possesses E3 ubiquitin ligase activity.
    Aso T; Yamazaki K; Aigaki T; Kitajima S
    Biochem Biophys Res Commun; 2000 Sep; 276(1):355-61. PubMed ID: 11006129
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renal cell carcinoma development in the rat independent of alterations at the VHL gene locus.
    Walker C; Ahn YT; Everitt J; Yuan X
    Mol Carcinog; 1996 Feb; 15(2):154-61. PubMed ID: 8599582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulin-like growth factor-1 signaling in renal cell carcinoma.
    Tracz AF; Szczylik C; Porta C; Czarnecka AM
    BMC Cancer; 2016 Jul; 16():453. PubMed ID: 27405474
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth.
    Baba M; Hirai S; Kawakami S; Kishida T; Sakai N; Kaneko S; Yao M; Shuin T; Kubota Y; Hosaka M; Ohno S
    Oncogene; 2001 May; 20(22):2727-36. PubMed ID: 11420685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
    Zbar B
    Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta.
    Pal S; Claffey KP; Cohen HT; Mukhopadhyay D
    J Biol Chem; 1998 Oct; 273(41):26277-80. PubMed ID: 9756852
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.
    Kondo K; Klco J; Nakamura E; Lechpammer M; Kaelin WG
    Cancer Cell; 2002 Apr; 1(3):237-46. PubMed ID: 12086860
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation.
    Lovell M; Lott ST; Wong P; El-Naggar A; Tucker S; Killary AM
    Cancer Res; 1999 May; 59(9):2182-9. PubMed ID: 10232606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFalpha cytotoxicity.
    Caldwell MC; Hough C; Fürer S; Linehan WM; Morin PJ; Gorospe M
    Oncogene; 2002 Jan; 21(6):929-36. PubMed ID: 11840338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent.
    Zhou MI; Wang H; Foy RL; Ross JJ; Cohen HT
    Cancer Res; 2004 Feb; 64(4):1278-86. PubMed ID: 14973063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.
    Schoenfeld A; Davidowitz EJ; Burk RD
    Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8817-22. PubMed ID: 9671762
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor.
    Zagzag D; Krishnamachary B; Yee H; Okuyama H; Chiriboga L; Ali MA; Melamed J; Semenza GL
    Cancer Res; 2005 Jul; 65(14):6178-88. PubMed ID: 16024619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene.
    Hughson MD; He Z; Liu S; Coleman J; Shingleton WB
    Cancer Genet Cytogenet; 2003 Jun; 143(2):145-53. PubMed ID: 12781449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.
    Gunaratnam L; Morley M; Franovic A; de Paulsen N; Mekhail K; Parolin DA; Nakamura E; Lorimer IA; Lee S
    J Biol Chem; 2003 Nov; 278(45):44966-74. PubMed ID: 12944410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.